



LANSEN PHARMACEUTICAL HOLDINGS LIMITED

朗生醫藥控股有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock code: 503)

13 August 2010

Dear Sir/Madam

Election of Language and Means of Receipt of Corporate Communications

Pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Articles of Association of Lansen Pharmaceutical Holdings Limited (the “Company”), the Company will make available the following options for you to elect for the receipt of future corporate communications (“Corporate Communications”) of the Company, which means any document(s) issued or to be issued by the Company for the information or action of any holders of its securities, including but not limited to (a) the directors’ report, its annual accounts together with a copy of the auditor’s report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form, in the following manners:

- (1) to read future Corporate Communications published on the Company’s website at www.lansen.com.cn (“Website Version”) in place of receiving printed copies, and receive a notification letter of the publication of the Corporate Communications on the website; or
- (2) to receive the printed English version of all future Corporate Communications only; or
- (3) to receive the printed Chinese version of all future Corporate Communications only; or
- (4) to receive both the printed English and Chinese versions of all future Corporate Communications.

In support of environmental protection and for the purpose of cost saving, the Company recommends you to select the Website Version. To make your election, please mark (x) in the appropriate box on the enclosed reply form (“Reply Form”) and sign and return it by post or hand delivery to the Company’s Hong Kong branch share registrar (the “Hong Kong Branch Share Registrar”), Tricor Investor Services Limited at 26/F, Tesbury Centre, 28 Queen’s Road East, Wanchai, Hong Kong. If your registered address is within Hong Kong, the enclosed envelope will be postage prepaid and you do not need to affix a stamp when returning your Reply Form. Otherwise, please affix appropriate postage.

If you do not complete the Reply Form and return it to the Hong Kong Branch Share Registrar at the address indicated above by 13 September 2010, you will be deemed to consent to receiving the Website Version only, and a printed notification letter of the publication of the Corporate Communications on the website will be sent to you. If an email address is provided by you in the Reply Form, an electronic version of the notification letter of the publication of the Corporate Communications on the website will be sent to you.

You have the right at any time by reasonable notice in writing to the Company (c/o Tricor Investor Services Limited) or by email to lansen-ecom@hk.tricorglobal.com to change the choice of language and means of receipt of the Corporate Communications. Even if you have chosen to receive all future Corporate Communications using electronic means but for any reason have difficulty in receiving or gaining access to the Corporate Communications, the Company will promptly upon your request send the Corporate Communications to you in printed form free of charge.

Please note that (a) printed copies of the English and Chinese versions of all future Corporate Communications will be available from the Company or the Hong Kong Branch Share Registrar upon request; and (b) the same will also be available on the Company’s website at www.lansen.com.cn and the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk.

Should you have any queries in relation to this letter, please call the Company’s Hong Kong Branch Share Registrar’s telephone hotline at (852) 2980 1333 during business hours from 9:00 a.m. to 6:00 p.m., Monday to Friday, excluding public holidays.

Yours faithfully,
For and on behalf of
Lansen Pharmaceutical Holdings Limited
Stephen Burnau Hunt
Chairman